We could not find any results for:
Make sure your spelling is correct or try broadening your search.
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy...
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
ProShares, a premier provider of ETFs, announced today forward and reverse share splits on 20 of its ETFs. The splits will not change the total value of a shareholder's investment...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -9.54 | -47.7477477477 | 19.98 | 20.495 | 10.11 | 242431 | 14.39573642 | CS |
4 | -14.16 | -57.5609756098 | 24.6 | 25.055 | 10.11 | 140146 | 18.03681844 | CS |
12 | 0.4196 | 4.18745758652 | 10.0204 | 26.11 | 10.0204 | 145175 | 18.68436372 | CS |
26 | 0.4196 | 4.18745758652 | 10.0204 | 26.11 | 10.0204 | 66917 | 18.68436372 | CS |
52 | 0.4196 | 4.18745758652 | 10.0204 | 26.11 | 10.0204 | 33989 | 18.68436372 | CS |
156 | 0.4196 | 4.18745758652 | 10.0204 | 26.11 | 10.0204 | 11360 | 18.68436372 | CS |
260 | -0.63 | -5.69105691057 | 11.07 | 26.11 | 8.28 | 9994 | 16.61148862 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions